A Multi Center, Open Label Study of the Human Anti TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease.
Phase of Trial: Phase III
Latest Information Update: 22 Jun 2013
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms ADHERE
- Sponsors Abbott Laboratories
- 31 Oct 2012 Planned number of patients added (960) as reported by European Clinical Trials Database record.
- 11 Jul 2011 Additional trial locations added as reported by ClinicalTrials.gov.
- 01 Oct 2010 New trial record.